In this video, Patrick Mooney, Novartis vice president and U.S. franchise head, discusses the company’s proactive approach to address safety concerns associated with Beovu treatment for wet age-related macular degeneration.
Novartis has created an independent safety review committee, initiated a safety label update for Beovu (brolucizumab-dbll) globally and commissioned a global panel of 100 medical experts to answer key questions relating to the occurrence of retinal vasculitis or retinal vascular occlusion associated with treatment.
Uncategorized